The University of Tokyo; Ltd.;Forerunner Pharma Research Co., Ltd.;Forerunner Pharma Research Co.
发明人:
Yoshida, Kenji,Ito, Hirotaka,Aburatani, Hiroyuki
申请号：
AU2007312367
公开号：
AU2007312367B2
申请日:
2007.10.12
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
Disclosed is a method for diagnosis of cancer, which is characterized by detecting anepiregulin (EREG) protein. It is found that the expression of an EREG is enhanced ata vary high frequency in a gene level or a protein level in gastrointestinal cancer,pulmonary adenocarcinoma, pancreatic cancer, gastric cancer or renal cancer. In the diagnosis or treatment of cancer, an antibody recognizing the EREG proteinis used. Also disclosed are a pharmaceutical composition, a cell proliferationinhibitor and an anti-cancer agent, each comprising an antibody capable of bindingto an EREG as an active ingredient. Further disclosed is a method for inducingcytopathy in an EREG-expressing cell or inhibiting the proliferation of an EREG-expressingcell, by contacting the EREG-expressing cell with an antibody capable of bindingto an EREG.
